🧬 BIOTECH CATALYST AI SCANNER — March WK2

Alex

06 Mar 2026 — 17 min read

Biotech enters the second week of March in a turbulent crosscurrent. The XBI ETF trades near $120–126, up roughly 2–4% year-to-date after a blistering 36% return in 2025 — but the first week of March has tested nerves hard. A dramatic escalation in the Middle East, with US-Israeli strikes against Iran prompting retaliatory missile launches and threats to Strait of Hormuz shipping, has triggered a sharp flight to safety across global markets. Oil prices surging toward $80/barrel, the US Dollar posting its strongest week since 2022, and the VIX spiking above 21 are not the conditions where speculative small-cap biotech typically thrives. On top of that, a 15% global tariff announced by the Trump administration is being implemented this week following the Supreme Court's IEEPA ruling, injecting another layer of macro uncertainty.

And yet — this is exactly the environment where catalyst-driven biotech setups can decouple from the broader market. Binary clinical events don't care about tariff rates or oil futures. While geopolitical turmoil compresses multiples across cyclical sectors, a positive Phase 3 readout or FDA approval still moves a $100M biotech the same way it would in calmer markets. This week's scanner surfaces several names sitting on near-term data catalysts, including two PDUFA decisions, multiple Phase 2/3 readouts due within weeks, and one stock trading at roughly half its cash value. The dislocation between macro fear and micro-cap biotech fundamentals is creating setups worth watching closely.

The scanner also flags a noteworthy development this week: PepGen (PEPG) disclosed that the FDA placed a partial clinical hold on its FREEDOM2-DM1 Phase 2 trial on March 4, related to preclinical pharmacology and toxicology questions. The stock dropped over 25% on the news. Dosing continues at international sites, and the company reiterates its Q1 2026 data guidance — but the hold introduces meaningful regulatory uncertainty into what had been one of the cleaner rare disease setups in the small-cap space.

What We're Tracking:

Trading Below Cash: ACET, ALXO, BCYC
Cash Pressure: MBRX, PCSA, REPL, OCGN, GLSI
Initial Data: MBRX, MLYS, KPTI, NVCR, ACET
Multi-Catalyst: None this week

FEATURED CATALYSTS

#1. MBRX — Moleculin Biotech Inc.

🎯 THE CATALYST
Event: Annamycin — Phase 1/2 Full Results in Acute myeloid leukemia (AML)
Date: Q1 2026 (Est.)
⭐ BSI SCORE: 8.96/10

Annamycin is a next-generation anthracycline designed to treat AML without cardiotoxicity, a major limitation of standard anthracyclines like doxorubicin. It binds DNA to inhibit cancer cell replication while avoiding heart tissue accumulation, potentially enabling safer, higher dosing in relapsed/refractory patients.

The Setup: With $11M market cap and just $603K cash, MBRX has zero runway, facing imminent dilution. Q1 2026 Phase 1/2 full results offer a high-stakes catalyst; positive data could spark multi-bagger upside from depressed valuation, but cash crunch pressures desperate financing terms.

Science & Edge: Annamycin encapsulates anthracycline to prevent myocardial uptake, delivering efficacy via topoisomerase II inhibition and DNA intercalation. Phase 1/2 prelim data (Jan 2022) showed clean safety — no cardiotoxicity up to FDA lifetime dose limits — in R/R AML patients. Unlike daunorubicin/doxorubicin, it sidesteps cumulative heart damage, allowing repeat dosing.

Risk/Reward:
🐂 Bull: Strong Q1 2026 data confirms efficacy with superior safety, triggering partnerships, NDA path, and re-rating.
🐻 Bear: Trial misses efficacy endpoints, cash exhaustion forces toxic dilution, or bankruptcy before catalyst.

#2. MNKD — MannKind Corporation

🎯 THE CATALYST
Event: Afrezza (Technosphere Insulin) - (INHALE-1) — PDUFA Regulatory Decision in Pediatric type 1/2 diabetes
Date: May 29, 2026
⭐ BSI SCORE: 7.93/10

Afrezza is an inhaled ultra-rapid-acting insulin using Technosphere technology to encapsulate insulin with fumaryl diketopiperazine for rapid lung absorption. It provides ~12-minute onset, peak in 35–55 minutes, mimicking natural insulin response better than injectables — enhancing postprandial control and convenience while reducing injection burden.

The Setup: $872M market cap with $166M cash supports 36+ month runway, minimizing dilution risk ahead of May 29, 2026 PDUFA for pediatric Type 1/2 diabetes. Strong Afrezza revenue growth (46% YoY to $74.6M in 2025) bolsters the position; approval could drive valuation re-rating via expanded market access despite modest current penetration.

Science & Edge: Afrezza's Technosphere particles enable ultra-rapid pulmonary absorption, onset ~12 min, peak 35–55 min, duration 90–270 min vs. slower injectables like lispro. Phase III data show HbA1c non-inferiority, superior postprandial glucose reduction (58%), lower severe hypoglycemia. Eliminates needles, improving adherence for mealtime dosing.

Risk/Reward:
🐂 Bull: Pediatric approval unlocks vast Type 1/2 market, boosts revenue >50%, ADA endorsement accelerates adoption, driving multi-fold valuation upside.
🐻 Bear: PDUFA rejection due to lung safety concerns in kids; slow uptake from reimbursement hurdles and physician inertia caps growth.

#3. PCSA — Processa Pharmaceuticals Inc.

🎯 THE CATALYST
Event: NGC-Capecitabine (PCS6422) — Phase 2 Interim Data in Breast cancer
Date: Q1 2026 (Est.)
⭐ BSI SCORE: 7.39/10

Processa modifies FDA-approved chemotherapies like capecitabine into Next Generation Cancer (NGC) drugs. PCS6422 (NGC-Cap) combined with capecitabine boosts exposure to the cancer-killing 5-FU metabolite by 2–10x while preserving safety, enabling higher efficacy without added toxicity versus standard capecitabine monotherapy.

The Setup: $6.46M market cap with $230K cash and <1-month runway signals acute dilution risk or shutdown pressure. $7M raised June 2025 via public offering, but funds depleted rapidly. Q1 2026 Phase 2 interim data looms as pivotal catalyst; positive readout could drive multi-fold re-rating on the micro-cap float, but cash crunch demands near-term financing.

Science & Edge: PCS6422 inhibits dihydropyrimidine dehydrogenase (DPD), reducing capecitabine metabolism to increase active 5-FU metabolite (FBMAC) exposure 2–10x. Phase 1b showed 66.7% PFS 5–11 months in GI cancer, all high-dose patients responded; Phase 2 in metastatic breast cancer ongoing. Enhances tumor kill while matching safety, avoiding DPD deficiency toxicities.

Risk/Reward:
🐂 Bull: Phase 2 interim exceeds benchmarks with superior PFS/ORR, partners emerge, stock surges on low float.
🐻 Bear: Cash exhaustion forces toxic dilution or bankruptcy before data; trial misses on efficacy/safety.

#4. MLYS — Mineralys Therapeutics Inc.

🎯 THE CATALYST
Event: Lorundrostat - (EXPLORE-OSA) — Phase 2 Topline Data in Obstructive Sleep Apnea and Hypertension
Date: Q1 2026 (Est.)
⭐ BSI SCORE: 7.35/10

Lorundrostat is a highly selective oral aldosterone synthase inhibitor (ASI) that reduces aldosterone by targeting CYP11B2 enzyme, addressing dysregulated aldosterone in hypertension, CKD, and OSA. It offers superior 24-hour BP control and safety vs. standard antihypertensives, targeting hard-to-treat patients where alternatives fail.

The Setup: $2.11B cap with $543M cash supports 36+ month runway amid no revenue. EXPLORE-OSA Phase 2 topline due Q1 2026 aligns with NDA filed late 2025 and ongoing long-term safety data. Recent $113M shelf for ESOP bolsters flexibility as valuation hinges on catalysts, minimizing dilution pressure short-term.

Science & Edge: Lorundrostat inhibits CYP11B2 for precise aldosterone reduction, lowering SBP and proteinuria in Phase 2 Target-HTN, Explore-CKD (met primary endpoint on SGLT2i background), and OSA trials. Unlike broad antihypertensives or less selective ASIs, it provides best-in-class 24-hour BP control with clean safety in uncontrolled/resistant hypertension and comorbidities.

Risk/Reward:
🐂 Bull: Q1 2026 EXPLORE-OSA success + NDA approval drives label expansions into CKD/OSA, blockbuster HTN revenue, partnerships, and multi-fold valuation re-rating.
🐻 Bear: EXPLORE-OSA misses, NDA rejection, or ASI competition erodes edge, prolonging cash burn and compressing valuation amid ongoing losses.

#5. ACET — Adicet Bio Inc.

🎯 THE CATALYST
Event: ADI-001 — Phase 2 End of Phase Meeting in Lupus nephritis and SLE
Date: Q1 2026 (Est.)
🛡️ FDA Status: FTD
⭐ BSI SCORE: 7.16/10

Adicet Bio develops ADI-001, an allogeneic γδ CAR-T therapy targeting CD20 on B cells for lupus nephritis and SLE. It induces deep B cell depletion and immune reset, enabling immunosuppressant discontinuation — unlike antibodies or T cell engagers requiring less invasive profiles.

The Setup: $71.46M market cap undervalues $144.18M cash and 18+ month runway into mid-2026. FDA meeting in Q1 2026 and Phase 2 start in Q2 align with sufficient funding, no immediate dilution pressure. Positive Phase 1 data could drive re-rating ahead of pivotal trial.

Science & Edge: ADI-001 engineers γδ T cells (primarily Vδ1+) to deplete CD20+ B cells without ICANS or severe CRS in Phase 1. All 7 lupus patients showed rapid SLEDAI-2K/PGA reductions; 3/5 LN achieved complete renal responses and DORIS remission with B cell reset. Requires lymphodepletion unlike TCEs, but offers durable remission vs. chronic therapy.

Risk/Reward:
🐂 Bull: Phase 2 data confirms immune reset, Fast Track accelerates approval, partnership or buyout at premium valuation.
🐻 Bear: Phase 2 misses endpoints, lymphodepletion toxicity halts progress, cash burn erodes runway.

#6. REPL — Replimune Group Inc.

🎯 THE CATALYST
Event: RP1 (vusolimogene oderparepvec) and OPDIVO (nivolumab) - (IGNYTE-3) — PDUFA Regulatory Decision in Non-melanoma (NMSC) / Non-small cell lung cancer (NSCLC)
Date: Apr 10, 2026
🛡️ FDA Status: BTD
⭐ BSI SCORE: 7.03/10

RP1 is an engineered oncolytic HSV expressing GALV-GP R- and GM-CSF, enabling direct tumor lysis, immunogenic cell death, and STING pathway activation for interferon responses. Combined with nivolumab, it inflames the tumor microenvironment and recruits neutrophils, boosting anti-tumor immunity beyond PD-1 monotherapy alone.

The Setup: With $221.50M cash and 10-month runway amid $581.31M market cap, Replimune faces acute pressure as funds near depletion before the April 10, 2026 PDUFA for RP1+Opdivo in NMSC/NSCLC. Approval could drive multi-fold valuation surge; rejection risks dilution or distress sale, amplifying binary catalyst dynamics.

Science & Edge: RP1 selectively replicates in tumors, expressing GALV for enhanced lysis and GM-CSF for immune recruitment, while triggering STING/IFN signaling that elevates PD-L1 on neutrophils/tumor cells and MHC-I on tumors, synergizing with nivolumab. IGNYTE trial showed 33% response rate vs. standard PD-1 alone; differs from SOC by adding oncolytic inflammation and abscopal effects in cold tumors like NMSC.

Risk/Reward:
🐂 Bull: PDUFA approval unlocks RP1+Opdivo launch in NMSC/NSCLC, generating peak sales >$1B, partnerships, and buyout at premium valuation.
🐻 Bear: PDUFA rejection on efficacy/safety triggers cash burn, dilution, or shutdown amid short runway.

#7. OCGN — Ocugen, Inc.

🎯 THE CATALYST
Event: OCU410 - (ArMaDa) — Phase 2 Full Results in Geographic Atrophy (GA)
Date: Q1 2026 (Est.)
⭐ BSI SCORE: 7.00/10

OCU410 (ArMaDa) is a novel AAV5-RORA modifier gene therapy that upregulates networks of protective genes to slow photoreceptor degeneration and GA lesion growth in dry AMD. Unlike approved complement inhibitors (pegcetacoplan, avacincaptad pegol) which slow growth but lack functional benefits and carry safety issues, OCU410 shows structural preservation with no serious adverse events.

The Setup: $571M market cap with $31M cash and 6-month runway creates dilution pressure amid FY25 losses and funding reliance. Phase 2 full data due March 2026 offers near-term catalyst; Phase 3 start 2026 targets BLA 2028. Positive prelim data (46% lesion reduction, p=0.015) supports valuation upside if executed, but cash burn demands financing soon.

Science & Edge: OCU410 delivers RORA gene via subretinal injection to enhance retinal cell survival. Phase 2 prelim: 46% GA lesion growth reduction vs. control (p=0.015, N=23), 54% medium-dose, 50% patients >50% reduction; Phase 1: 60% slower ellipsoid zone loss vs. untreated eyes. Targets disease modification with photoreceptor preservation, functional potential, and clean safety — a step beyond complement inhibitors.

Risk/Reward:
🐂 Bull: Full Phase 2 confirms/improves data, Phase 3 initiates 2026, BLA 2028 succeeds; gene therapy edge captures GA market lacking functional therapies.
🐻 Bear: Full data disappoints, cash depletes forcing dilutive financing, Phase 3 delays amid competition.

#8. KPTI — Karyopharm Therapeutics Inc.

🎯 THE CATALYST
Event: Selinexor (XPORT-MF-034) - (SENTRY) — Phase 3 Topline Data in JAKi-naïve myelofibrosis versus ruxolitinib alone
Date: Q1 2026 (Est.)
🛡️ FDA Status: FTD
⭐ BSI SCORE: 6.97/10

Selinexor is a first-in-class oral XPO1 inhibitor that blocks nuclear export, trapping tumor suppressor proteins in cancer cell nuclei to induce apoptosis. In JAKi-naïve myelofibrosis, it combines with ruxolitinib in the Phase 3 SENTRY trial to enhance spleen volume reduction and symptom relief beyond ruxolitinib monotherapy, which achieves SVR35 in only ~33% of patients.

The Setup: $162M market cap reflects high-risk biotech valuation ahead of March 2026 SENTRY topline. $55M cash funds operations only into Q2 2026, creating acute runway pressure and likely need for dilution via financing or partnership post-data, especially if positive and requiring commercialization ramp-up.

Science & Edge: Selinexor inhibits XPO1, disrupting multiple myelofibrosis pathways like inflammation and fibrosis when added to ruxolitinib. Phase 3 SENTRY (n=353, 2:1 randomization) tests co-primaries: SVR35 at week 24 and symptom score change. Preliminary safety shows improved hematologic profile vs. prior data; addresses ruxolitinib limitations like anemia in >30% and transfusions.

Risk/Reward:
🐂 Bull: SENTRY succeeds, delivering superior SVR35/symptoms vs. ruxo alone, enabling $1B peak myelofibrosis sales, label expansion, partnership, and multi-fold stock re-rating.
🐻 Bear: SENTRY misses endpoints or safety issues emerge, triggering cash burn acceleration, dilution, or shutdown amid short runway.

#9. PEPG — PepGen Inc.

🎯 THE CATALYST
Event: PGN-EDODM2 - (FREEDOM-DM1/2) — Phase 1/2 in Myotonic dystrophy type 1 (DM1)
Date: Q1 2026 (Est.)
🛡️ FDA Status: FTD, ODD
⭐ BSI SCORE: 6.89/10

PepGen develops PGN-EDODM2, an enhanced DNA oligonucleotide using its EDO platform for myotonic dystrophy type 1 (DM1). It promotes exon-skipping to correct toxic DMPK mRNA splicing, addressing the root cause of muscle weakness and multisystem symptoms. Unlike symptomatic treatments, it offers disease-modifying potential with superior tissue penetration.

The Setup: With $137M cash and 24+ month runway, PepGen faces no immediate funding pressure into 2027. The $380M market cap reflects Phase 1/2 valuation ahead of Q1 2026 5 mg/kg MAD data. However, the FDA placed a partial clinical hold on the FREEDOM2-DM1 Phase 2 trial on March 4, 2026, citing questions about preclinical pharmacology and toxicology studies — not clinical data from FREEDOM. The stock dropped over 25% on the news. No US patients had been enrolled at the time of the hold. Dosing continues at 10 mg/kg in the UK and Canada, and the company reiterates its Q1 2026 data guidance for the 5 mg/kg cohort and 2H 2026 for the 10 mg/kg cohort. Positive readout and rapid hold resolution could restore momentum; prolonged hold raises regulatory risk for US development.

Science & Edge: PGN-EDODM2 (and analog PGN-EDODM1) uses EDOs for durable exon 1 skipping in DM1, reducing nuclear RNA foci. Phase 1 SAD showed 53.7% mean splicing correction at a single 15 mg/kg dose (Sep 2025). Key edges over competing ASOs include higher potency, longer duration, and better CNS/muscle delivery vs. IV standards of care.

Risk/Reward:
🐂 Bull: Q1 2026 data confirms SAD efficacy in MAD, hold lifts swiftly; partnerships or buyout at premium propel shares to $20+ ahead of Phase 3.
🐻 Bear: Hold signals underlying toxicity; data disappoints on efficacy/durability, burning cash with no near-term milestones.

#10. CLNN — Clene Inc.

🎯 THE CATALYST
Event: CNM-Au8 - (HEALEY ALS) — Phase 2/3 End of Phase Meeting in Amyotrophic Lateral Sclerosis (ALS)
Date: Q1 2026 (Est.)
⭐ BSI SCORE: 6.84/10

Clene develops CNM-Au8, nanostructured gold nanocrystals that enhance neuronal energy metabolism and reduce oxidative stress in ALS. This targets neurodegeneration at its bioenergetic root, potentially slowing disease progression more effectively than symptom-managing alternatives like Riluzole or Edaravone.

The Setup: With $57.5M market cap and $29M cash, Clene's 18+ month runway aligns with Q1 2026 Type C FDA meeting on HEALEY ALS Phase 2/3 data. The HEALEY survival readout (median 951 vs. 753 days, +198 days in the 30mg arm) could drive re-rating from depressed valuation. Cash is adequate but limited for Phase 3 advancement without partnership.

Science & Edge: CNM-Au8 acts as a mitochondrial catalyst, improving NAD+/NADH ratios and ATP production in motor neurons, addressing ALS's core energy deficits. HEALEY data: 30mg arm median survival 951 days (+198 days vs. control), slowed functional decline (ALSFRS-R). Unlike SOC Riluzole (modest 2–3 month extension), it offers disease-modifying potential via novel nano-gold mechanism.

Risk/Reward:
🐂 Bull: Strong Type C meeting yields Phase 3 path, partnership/BLA filing; survival data validates label, stock surges 5–10x on buyout or approval trajectory.
🐻 Bear: FDA rejects data for Phase 3 advancement due to trial design or subgroup issues; cash burn erodes runway without funding.

WATCHLIST

#11. NVCR — NovoCure Limited [Oncology]

📊 Price: $14.23 | Cap: $1.62B | Cash: $434.67M | RSI: 59.4 | Momentum: +23.1% 🎯 Tumor Treating Fields (TTFields) - (PANOVA-4) — Phase 2 Topline Data in Metastatic pancreatic cancer (Q1 2026 (Est.)) ⭐ BSI: 7.21/10

The Intel: NovoCure's TTFields deliver low-intensity alternating electric fields to disrupt cancer cell division — a non-invasive, drug-free modality. PANOVA-4 targets metastatic pancreatic cancer, one of oncology's most treatment-resistant indications. With $435M cash, 72-month runway, and 2026 FDA approval of Optune Pax in the US, the company has deep resources. The risk is whether TTFields can move the needle in pancreatic cancer where so many therapies have failed.

#12. GLSI — Greenwich LifeSciences Inc. [Oncology]

📊 Price: $24.67 | Cap: $341.79M | Cash: -$852.9K | RSI: 46.5 | Momentum: -8.7% 🎯 GP2 (GLSI-100) - (FLAMINGO-01) — Phase 3 Conference Presentation in HER2 positive breast cancer (Apr 17, 2026) 🛡️ FTD ⭐ BSI: 6.84/10

The Intel: GP2 is a peptide cancer vaccine designed to stimulate cytotoxic T-cells against HER2/neu, reducing recurrence after surgery. The open-label non-HLA-A*02 arm reported an 80% recurrence reduction, and DSMB recommended the trial increase size and continue enrolling past interim. AACR presentation on April 17 could catalyze attention. Cash position is severely strained, though the low float amplifies any move. Key risk: vaccine immunology in adjuvant breast cancer has a mixed track record.

#13. ALXO — ALX Oncology Holdings Inc. [Oncology]

📊 Price: $2.13 | Cap: $115.48M | Cash: $180.81M | RSI: 40.0 | Momentum: +6.0% 🎯 Zanidatamab and Evorpacept (ALX148) — Phase 1/2 Conference Presentation in HER2 Breast cancer and solid tumors (May 07, 2026) ⭐ BSI: 6.79/10

The Intel: ALX trades at a steep discount to cash — $115M market cap vs. $181M in the bank. Evorpacept blocks CD47 "don't eat me" signals to boost phagocytosis, combined with zanidatamab's HER2-targeting. Early data suggests benefit concentrated in patients with higher CD47 expression, which narrows the addressable population but may sharpen the responder profile. ESMO Breast presentation in May is the next read. With 31-month runway, no near-term dilution pressure.

#14. EDSA — Edesa Biotech Inc. [Immunology/Inflammation]

📊 Price: $3.61 | Cap: $30.14M | Cash: $10.54M | RSI: 77.0 | Momentum: +231.2% 🎯 Paridiprubart - (EB05) — Phase 3 Conference Presentation in COVID-19, ARDS (May 15, 2026) 🛡️ FTD ⭐ BSI: 6.77/10

The Intel: Paridiprubart is a monoclonal antibody inhibiting complement factor C5a in ARDS. The Phase 3 hit its primary endpoint in the full 278-patient treatment population (reported Feb 24, 2026), a significant clinical milestone. Stock has surged >230% on momentum. ATS 2026 presentation in May will provide detailed data. The core question is whether ARDS driven by COVID-19 inflammation has enough residual commercial relevance in 2026, or whether the mechanism can be broadened to non-COVID ARDS settings.

#15. IOVA — Iovance Biotherapeutics Inc. [Oncology]

📊 Price: $4.58 | Cap: $1.89B | Cash: $258.99M | RSI: 93.6 | Momentum: +87.7% 🎯 IOV-4001 — Phase 1 Full Results in Metastatic melanoma and NSCLC (Q1 2026 (Est.)) ⭐ BSI: 6.73/10

The Intel: Iovance is commercial-stage with Amtagvi, the first FDA-approved TIL therapy for solid tumors. IOV-4001 represents next-gen innovation — TIL with PD-1 inactivated via gene editing. Phase 1 data in melanoma and NSCLC could validate the approach. Stock is overbought at RSI 93.6 after an 88% run, suggesting the market is pricing in significant optimism. The company's commercial infrastructure gives it a development edge, but near-term upside may already be captured in the price.

#16. NBP — NovaBridge Biosciences [Oncology]

📊 Price: $3.64 | Cap: $418.58M | Cash: $173.40M | RSI: 64.7 | Momentum: +6.4% 🎯 Givastomig (CLDN18.2 x 4-1BB bispecific antibody) — Phase 1b Full Results in HER2-negative metastatic gastric cancer (Q1 2026 (Est.)) 🛡️ ODD ⭐ BSI: 6.71/10

The Intel: Givastomig targets CLDN18.2 and co-stimulates via 4-1BB, a differentiated bispecific approach in gastric cancer. Phase 1b data showed 77% ORR at 8 mg/kg and 73% at 12 mg/kg in first-line HER2-negative gastric cancer, with 16.9-month median PFS. Efficacy appeared independent of CLDN18.2 and PD-L1 expression levels, which would be a meaningful advantage over biomarker-restricted competitors. Phase 2 enrollment beginning Q1 2026.

#17. ANVS — Annovis Bio Inc. [Neurology]

📊 Price: $2.48 | Cap: $65.73M | Cash: $15.20M | RSI: 51.7 | Momentum: -3.9% 🎯 Buntanetap — Phase 3 Conference Presentation in Parkinson's Disease (Mar 17, 2026) ⭐ BSI: 6.68/10

The Intel: Buntanetap targets translation of multiple neurotoxic proteins (APP, tau, α-synuclein, TDP-43) via RNA mechanisms — a broad multi-target approach to neurodegeneration. Additional PD data will be shared at the AD/PD conference March 17–21. In PD trials, buntanetap reportedly halted cognitive decline with biomarker benefits concentrated in mild dementia patients. Controversy persists around trial design and whether cognitive effects translate to clinically meaningful outcomes.

#18. BCYC — Bicycle Therapeutics plc [Oncology]

📊 Price: $5.35 | Cap: $371.12M | Cash: $524.14M | RSI: 49.7 | Momentum: -6.5% 🎯 Zelenectide pevedotin (BT8009) - (Duravelo-2) — Phase 1/2 End of Phase Meeting in Solid tumors (Q1 2026 (Est.)) 🛡️ FTD ⭐ BSI: 6.67/10

The Intel: Bicycle Toxin Conjugates combine the binding specificity of biologics with small-molecule tissue penetration — a novel drug modality. BT8009 targets nectin-4 with 60% ORR reported at SABCS and 45% at ESMO with 11.1-month median duration of response. Cash of $524M exceeds the $371M market cap, creating a clear negative EV setup. Regulatory feedback expected Q1 2026 will shape the pivotal trial path. The question is whether BTCs can carve a niche against established ADCs in the nectin-4 space.

#19. CTMX — CytomX Therapeutics Inc. [Oncology]

📊 Price: $4.77 | Cap: $808.21M | Cash: $116.50M | RSI: 37.1 | Momentum: -15.9% 🎯 Varsetatug masetecan (CX-2051) — Phase 1 Interim Data in Solid Tumors (Q1 2026 (Est.)) ⭐ BSI: 6.66/10

The Intel: CytomX's PROBODY platform creates masked antibodies that activate only in the tumor microenvironment, reducing off-target toxicity. CX-2051 targets EpCAM — previously undruggable due to healthy tissue expression — with a topo-1 ADC payload. Phase 1 interim showed 28% ORR overall and 43% at 10 mg/kg. Additional data and combo trial initiation expected Q1 2026. Partnership with AbbVie (via ImmunoGen acquisition) validates platform interest. Momentum is negative, suggesting the market wants more convincing dose-response data.

#20. ADAG — Adagene Inc. [Oncology]

📊 Price: $3.02 | Cap: $142.34M | Cash: $85.19M | RSI: 56.4 | Momentum: +6.3% 🎯 Muzastotug (ADG126) combined with KEYTRUDA (pembrolizumab) - (ADG126-P001/KEYNOTE-C98) — Phase 2 Interim Data in Solid tumors (Q1 2026 (Est.)) 🛡️ FTD ⭐ BSI: 6.51/10

The Intel: Adagene's SAFEbody platform engineers masked anti-CTLA-4 antibodies that activate in the tumor microenvironment, minimizing the systemic toxicity that limits ipilimumab. Muzastotug combined with pembrolizumab in KEYNOTE-C98 targets solid tumors including MSS colorectal cancer — one of immunotherapy's toughest battlegrounds. FDA alignment on Phase 2 endpoints gained in mid-2025. Interim data expected Q1 2026 will determine whether the masking approach translates to a better therapeutic window than competing CTLA-4 agents.

The Strategist's Take

This week's scanner is loaded with near-term catalysts against an unusually volatile macro backdrop. The Middle East escalation and tariff implementation are compressing risk appetite broadly, but the biotech catalyst calendar doesn't pause for geopolitics. Six of our top ten featured names have data or regulatory events expected within the current quarter.

The standout deep-value setup remains ACET (BSI: 7.16) — trading at roughly half its cash value with an FDA End of Phase meeting imminent and 19 months of runway. The CAR-T autoimmune space has been red-hot, and ADI-001's Phase 1 data in lupus showed clean safety with durable responses. If the FDA meeting goes well, this name has significant room to re-rate before Phase 2 even starts. On the watchlist, BCYC (BSI: 6.67) presents a similar negative EV dynamic with $524M in cash against a $371M market cap — and a clinical-stage asset with 60% ORR data.

At the other end of the risk spectrum, MBRX (BSI: 8.96) and PCSA (BSI: 7.39) are textbook cash-crunch binary plays. Both have sub-$1M in cash with data due this quarter. These are the setups where a positive readout can generate explosive returns on micro-floats, but where the financing pressure makes them genuinely uninvestable for anyone without a high tolerance for total loss. The two PDUFA catalysts — MNKD (May 29) and REPL (April 10) — offer cleaner binary risk at larger market caps.

Finally, the PEPG situation deserves close monitoring. The partial clinical hold is a meaningful negative, but the nuances matter: the hold relates to preclinical tox questions, not clinical safety signals; no US patients were enrolled; and dosing continues internationally. The 4.65x volume spike tells you the market reacted sharply. If PepGen can resolve the FDA's questions quickly and Q1 data from the 5 mg/kg cohort is strong, this could become a compelling re-entry point. If the hold drags, the regulatory overhang will weigh on sentiment regardless of the clinical data.

About This Scanner

This weekly report identifies biotech catalyst opportunities using quantitative screening combined with fundamental analysis.

What the Score Means: The BSI Score (0-10) reflects overall opportunity quality based on technical setup and fundamental characteristics. Higher scores indicate more favorable setups; lower scores indicate elevated uncertainty. This is NOT a prediction of catalyst outcomes or stock direction.

Data Sources: Financial data from market feeds and regulatory filings. Catalyst dates are estimates based on company guidance and subject to change.

Important: This report is for informational and educational purposes only. It does not constitute investment, financial, or medical advice. Conduct your own due diligence before making investment decisions.

Disclaimer

The information provided is for informational purposes only and should not be construed as financial, investment, legal, or professional advice.

Key Risks:

Clinical trials: Most drug candidates fail in development
Regulatory: FDA decisions remain unpredictable
Financing: Companies may dilute at any time
Volatility: Small-cap biotech stocks experience extreme price swings

Past performance does not guarantee future results.